This content is from: Premium
Short Sellers Won in Mallinckrodt Mess, but Some Hedgies Held On
The specialty pharmaceutical company settled opioid lawsuit and is considering restructuring.
It took the opioid epidemic to finally bring down specialty pharmaceutical company Mallinckrodt, whose fall from Wall Street grace seems almost complete. Just two days after a report it was considering a bankruptcy filing, Mallinckrodt said it had agreed to the biggest settlement yet by opioid manufacturers — for $30
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.